Investors

Press Releases

 
Press Releases
  Date Title View
Dec 19, 2016
- Company to Submit MAA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections to the EMA in Second Half of 2017 - - Phase 3 IGNITE3 Study in Complicated Urinary Tract Infections to Commence in First Quarter of 2017 - WATERTOWN, Mass., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a ...
Nov 17, 2016
WATERTOWN, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the publication of results from IGNITE1, the Company's phase 3 clinical trial which evaluated er...
Nov 7, 2016
WATERTOWN, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the Stifel 2016 Healthcare Conferen...
Nov 3, 2016
WATERTOWN, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the third quarter ended September 30, 2016, and highlighted recent clinical...
Oct 26, 2016
WATERTOWN, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced eight data presentations at IDWeek 2016, taking place October 26-30 in New Orleans, LA.  Presentations will include information about the company's phase 3 antibiotic candidate, eravacycline, with data demonstrating consistent and po...
Oct 14, 2016
Top-line IGNITE4 Data Expected in 4Q 2017 Results to Support NDA Filing for IV Eravacycline in cIAI WATERTOWN, Mass., Oct. 14, 2016 (GLOBE NEWSWIRE) --  Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced dosing of the first patient in IGNITE4, the Company's phase 3 clinical trial evaluating the efficacy and safety of intrave...
Aug 8, 2016
WATERTOWN, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the Wedbush PacGrow Healthcare Con...
Aug 4, 2016
WATERTOWN, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the second quarter ended June 30, 2016, and provided an overview of certain...
Aug 1, 2016
WATERTOWN, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the initiation of patient dosing in a phase 1 clinical trial for intravenous (IV) TP-6076, a novel antibiotic candidate being developed for the treatment of serious and life-threatening bacterial infections, including those caused by...
Jun 28, 2016
WATERTOWN, Mass., June 28, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that it was added to the Russell Microcap® Index when the Russell Investment Group reconsti...
FirstPrevious
2
...
NextLast
= add release to Briefcase